Workflow
DiaMedica Therapeutics(DMAC)
icon
Search documents
DiaMedica Therapeutics(DMAC) - 2022 Q1 - Quarterly Report
2022-05-03 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Voting common shares, no par value per share DMAC The Nasdaq Stock Market LLC FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ...
DiaMedica Therapeutics(DMAC) - 2021 Q4 - Earnings Call Transcript
2022-03-15 16:20
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2021 Earnings Conference Call March 15, 2022 8:00 AM ET Company Participants Rick Pauls - President & Chief Executive Officer Kirsten Gruis - Chief Medical Officer Dominic Cundari - Chief Commercial Officer Scott Kellen - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Fourth Quarter 2021 Conference Call. An audio recording of the we ...
DiaMedica Therapeutics(DMAC) - 2021 Q4 - Annual Report
2022-03-13 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________. Commission file number: 001-36291 ____________________ DIAMEDICA THERAPEUTICS INC. (Exact na ...
DiaMedica Therapeutics(DMAC) - 2021 Q3 - Earnings Call Transcript
2021-11-11 15:07
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2021 Earnings Conference Call November 11, 2021 8:00 AM ET Company Participants Rick Pauls - President, CEO & Director Scott Kellen - CFO & Company Secretary Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Thomas Flaten - Lake Street Capital Markets Francois Brisebois - Oppenheimer Operator Good morning, ladies and gentlemen and welcome to the DiaMedica Therapeutics Third Quarter 2021 Conference Call. An audio recording of the webcast will be ...
DiaMedica Therapeutics(DMAC) - 2021 Q3 - Quarterly Report
2021-11-09 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‐‐ For the transition period from ________________ to __________________. Commission File Number: 001-36291 ____________________ DIAMEDICA THERAPEUTICS INC ...
DiaMedica Therapeutics(DMAC) - 2021 Q2 - Earnings Call Transcript
2021-08-12 15:11
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2021 Earnings Conference Call August 12, 2021 8:00 AM ET Company Participants Rick Pauls - President, CEO & Director Scott Kellen - CFO & Company Secretary Conference Call Participants Etzer Darout - Guggenheim Securities Alex Nowak - Craig-Hallum Capital Thomas Flaten - Lake Street Capital Francois Brisebois - Oppenheimer Operator Good morning, ladies and gentlemen. And welcome to the DiaMedica Therapeutics Second Quarter 2021 Conference Call. An audio recording ...
DiaMedica Therapeutics(DMAC) - 2021 Q2 - Quarterly Report
2021-08-10 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Voting common shares, no par value per share DMAC The Nasdaq Stock Market LLC FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‐‐ For the transition period from __ ...
DiaMedica Therapeutics(DMAC) - 2021 Q1 - Earnings Call Transcript
2021-05-09 20:31
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2021 Earnings Conference Call May 6, 2021 8:00 AM ET Company Participants Rick Pauls - President & Chief Executive Officer Scott Kellen - Chief Financial Officer Harry Alcorn - Chief Medical Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital Group Etzer Darout - Guggenheim Partners Francois Brisebois - Oppenheimer & Co. Inc. Thomas Flaten - Lake Street Capital Markets, LLC Elemer Piros - ROTH Capital Partners Jason McCarthy - Maxim Group, ...
DiaMedica Therapeutics(DMAC) - 2021 Q1 - Quarterly Report
2021-05-04 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Voting common shares, no par value per share DMAC The Nasdaq Stock Market LLC FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‐‐ For the transition period from _ ...
DiaMedica Therapeutics(DMAC) - 2020 Q4 - Earnings Call Transcript
2021-03-11 18:11
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2020 Results Earnings Conference Call March 11, 2021 8:00 AM ET Company Participants Rick Pauls - President & CEO Scott Kellen - CFO Harry Alcorn - Chief Medical Officer Conference Call Participants Alex Nowak - Craig-Hallum Etzer Darout - Guggenheim Elemer Piros - ROTH Capital Partners Thomas Flaten - Lake Street Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Fourth Quarter 2020 Conference Call. An audio re ...